TB-500 Fragment

Overview

TB-500 Fragment is catalogued as the short-fragment presentation of TB-500, the synthetic peptide derived from Thymosin beta-4. Where the standalone TB-500 SKU is the full 43-residue chain, this SKU is the abbreviated fragment preparation built around the actin-binding region of the parent molecule, the segment carrying the LKKTETQ motif that the Thymosin beta-4 literature identifies as the core of actin sequestration. Because fragment nomenclature is not standardised across suppliers and the same trade name is used for more than one set of residue boundaries, Vialdyne does not publish a fixed sequence, molecular formula, or CAS for this SKU. The fragment boundaries, measured mass, and identity for the material you are quoted are listed on batch COA, and that document, not a catalogue descriptor, is the record a receiving quality system should qualify against. Vialdyne releases TB-500 Fragment as a lyophilised powder against a ≥99.0% main-peak HPLC specification, in 5 mg and 10 mg fills. Two documentation points matter more here than on a full-length SKU. First, positive identity: ask for the ESI-MS result and the stated fragment boundaries on the offered lot before the material enters a qualification file, since a shorter chain is materially cheaper to synthesise than the 43-mer and mass alone is the only thing that separates the two presentations on paper. Second, do not carry a TB-500 acceptance record across to this SKU; the two are catalogued and released as separate materials, with their own lot numbers and their own certificates. Buyers who want the full-length chain should order the [TB-500](/catalog/tb-500) SKU, and the co-lyophilised BPC-157 pairing remains the [Wolverine Blend](/catalog/wolverine-blend), which is built on full-length TB-500 rather than on this fragment.

Applications & buyer fit

Repair peptides, BPC-157, TB-500, and related sequences, typically ship to research labs studying tissue-repair, gastrointestinal, or tendon-ligament models, and to compounding pharmacies that have validated the active material into their workflow. Buyers should request the batch COA for the lot offered or shipped and define any sequence-level evidence required by their written qualification procedure before quotation; Vialdyne does not require buyers to repeat the lot-release tests recorded on the COA.

Primary buyer fit: 503A / 503B compounding pharmacies and academic and contract research laboratories.

Specifications

CAS

No single public CAS for the fragment presentation; identity listed on batch COA

Appearance

White to off-white lyophilized powder

Purity (HPLC)

≥ 99.0%

Strength

5 mg – 10 mg

Packaging

10 vials/box · base pack (multiples of 10)

MOQ

On request

Lead time

7–14 days

Storage

-20°C lyophilized; 2–8°C reconstituted, protect from light

Certificate of Analysis

Representative COA previews for TB-500 Fragment; request the certificate matched to the offered or supplied lot from sales. These are previews — request the full high-resolution certificate for any lot.

VerifiedRequest full COA →

TB-500 Fragment

VD260428-TBF196 · 99.09%

Regulatory note

Supplied as a research-use reference material; not for human or veterinary use, and not approved as a finished drug in any jurisdiction. The July 2026 FDA PCAC item is written against TB-500 itself and should not be read as covering a fragment presentation. Buyers are responsible for confirming regulatory status in the destination market before use.

Frequently asked questions